atezolizumab
Overall Survival Benefit Achieved With First-Line Checkpoint Inhibitor in High-Risk NSCLC
In patients with non-small cell lung cancer (NSCLC) ineligible for standard chemotherapy, a first-line checkpoint ...
NOVEMBER 10, 2022
FDA Grants New Breast Cancer Indication for Genentech’s Tecentriq
The FDA granted a new indication for Tecentriq plus chemotherapy for the treatment of adults with unresectable ...
MARCH 12, 2019
Tecentriq Combo Approved for First-Line Rx of Metastatic Nonsquamous NSCLC
The FDA approved atezolizumab (Tecentriq, Genentech) in combination with bevacizumab (Avastin, Genentech), ...
DECEMBER 19, 2018
FDA Modifies Indications of Pembrolizumab, Atezolizumab
The FDA modified the urethal cancer indications of Keytruda and Tecentriq, limiting their use to patients who are ...
JULY 3, 2018
FDA Warns of Decreased Survival in Some UC Patients on Keytruda or Tecentriq
The FDA issued an alert about decreased survival associated with the use of pembrolizumab (Keytruda, Merck) or ...
MAY 21, 2018
Panel: Immunotherapy for Cancer Still in Its Infancy
National Harbor, Md.—While immunotherapy has been extremely successful for some patients, it’s still ...
FEBRUARY 16, 2017
FDA Approves Tecentriq for Urothelial Carcinoma
Tecentriq is the only anti–PD-L1 cancer immunotherapy approved by the FDA.
MAY 19, 2016
